---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-213655"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2022-08-05T23:59:59+00:00"
generated_at: "2026-06-24T03:27:54.672067+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics enters amended intercompany services agreement with Agenus effective April 1, 2022

## Summary
- New agreement covers G&A, R&D, and shared services; MiNK pays 10% of Agenus' G&A costs.
- R&D services charged at pass-through costs plus allocation of employee costs.
- Shared services no charge if proportional; facility/insurance use with proportionate payment.
- Either party may terminate with 60 days' notice; individual services 30 days.
- Agreement retroactive to April 1, 2022, amends September 2021 agreement.

## SEC filing metadata
- accession: 0001193125-22-213655
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2022-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000119312522213655/0001193125-22-213655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000119312522213655/d357005d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-213655
- JSON: https://secwatch.observer/filing/0001193125-22-213655.json
- Plain text: https://secwatch.observer/filing/0001193125-22-213655.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.